Ferreras C, Pascual-Miguel B, Mestre-Durán C, Navarro-Zapata A, Clares-Villa L, Martín-Cortázar C, De Paz R, Marcos A, Vicario J L, Balas A, García-Sánchez F, Eguizabal C, Solano C, Mora-Rillo M, Soria B, Pérez-Martínez A
Hospital La Paz Institute for Health Research, IdiPAZ, University Hospital La Paz, Madrid, Spain.
Hematology Department, University Hospital La Paz, Madrid, Spain.
Front Cell Dev Biol. 2021 Feb 25;9:620730. doi: 10.3389/fcell.2021.620730. eCollection 2021.
Syndrome coronavirus 2 (SARS-CoV-2) pandemic is causing a second outbreak significantly delaying the hope for the virus' complete eradication. In the absence of effective vaccines, we need effective treatments with low adverse effects that can treat hospitalized patients with COVID-19 disease. In this study, we determined the existence of SARS-CoV-2-specific T cells within CD45RA memory T cells in the blood of convalescent donors. Memory T cells can respond quickly to infection and provide long-term immune protection to reduce the severity of COVID-19 symptoms. Also, CD45RA memory T cells confer protection from other pathogens encountered by the donors throughout their life. It is of vital importance to resolve other secondary infections that usually develop in patients hospitalized with COVID-19. We found SARS-CoV-2-specific memory T cells in all of the CD45RA subsets (CD3, CD4, and CD8) and in the central memory and effector memory subpopulations. The procedure for obtaining these cells is feasible, easy to implement for small-scale manufacture, quick and cost-effective, involves minimal manipulation, and has no GMP requirements. This biobank of specific SARS-CoV-2 memory T cells would be immediately available "off-the-shelf" to treat moderate/severe cases of COVID-19, thereby increasing the therapeutic options available for these patients.
严重急性呼吸综合征冠状病毒2（SARS-CoV-2）大流行正在引发第二次疫情爆发，大大推迟了彻底根除该病毒的希望。在缺乏有效疫苗的情况下，我们需要副作用小的有效治疗方法来治疗新冠肺炎住院患者。在这项研究中，我们确定了康复供体血液中CD45RA记忆T细胞内存在SARS-CoV-2特异性T细胞。记忆T细胞能够对感染迅速做出反应，并提供长期免疫保护，以减轻新冠肺炎症状的严重程度。此外，CD45RA记忆T细胞还能保护供体免受其一生中遇到的其他病原体的侵害。解决通常在新冠肺炎住院患者中发生的其他继发感染至关重要。我们在所有CD45RA亚群（CD3、CD4和CD8）以及中央记忆和效应记忆亚群中发现了SARS-CoV-2特异性记忆T细胞。获取这些细胞的程序是可行的，易于小规模生产实施，快速且具有成本效益，操作极少，并且无需符合药品生产质量管理规范要求。这个特定的SARS-CoV-2记忆T细胞生物样本库将可以“现货供应”，立即用于治疗中度/重度新冠肺炎病例，从而增加这些患者可用的治疗选择。
